ABVC shares are trading higher after the company announced it entered into a term sheet to license the global rights of CNS drugs with the indications of MDD and ADHD to AiBtl BioPharma at the valuation of $667 million.
Portfolio Pulse from Benzinga Newsdesk
ABVC BioPharma has entered into a term sheet to license the global rights of CNS drugs for MDD and ADHD to AiBtl BioPharma. The deal is valued at $667 million, which has led to a rise in ABVC's share price.
October 26, 2023 | 12:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ABVC BioPharma's shares are trading higher after the company announced a licensing deal with AiBtl BioPharma valued at $667 million.
The licensing deal with AiBtl BioPharma, valued at $667 million, is a significant financial move for ABVC BioPharma. This has led to increased investor confidence, reflected in the rise of ABVC's share price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100